Clinical trials reveal targeted therapy increases the risk of neoplasms in chronic lymphocytic leukemia patients.
Key Points
The aim is to evaluate the occurrence of other cancers in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received various treatments.
Identified newly diagnosed CLL/SLL patients from 2016 using cancer registries and databases.
Reviewed electronic health records for treatments and occurrence of other cancers.
Categorized treatments into chemoimmunotherapy, targeted therapies, or combinations.
6844 CLL/SLL patients were evaluated with a median follow-up of 3.6 years.
583 patients developed other cancers, with prostate, lung, and hematologic malignancies being the most common.
Risk of other cancers increased by 40% in patients receiving CLL directed therapy compared to those who did not.